Visit
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
EHA 2021
Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:
🎥: http://ow.ly/hq9y50JGpAF
@EHA_Hematology #EHA2022 #RareDiseases #BPDCN
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.
Find out more here:
👉http://ow.ly/QqNu50JJj3z👈
#LymSM #HemOnc #CARTcell #ImmunoOnc
EHA 2021
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
Marco Herling of @UniLeipzig discusses the safety and efficacy of tagraxofusp for the treatment of BPDCN:
🎥: http://ow.ly/hq9y50JGpAF
@EHA_Hematology #EHA2022 #RareDiseases #BPDCN
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
📣 Our latest podcast is now live! Join UK experts Graham Jackson & Martin Kaiser as they discuss myeloma treatment in the UK, highlighting updates from Muk Nine b: OPTIMUM, the importance of chromosome 1q & more!
🎧: http://ow.ly/Rmji50JGF6U
#MMsm #HemOnc #Myeloma
On June 24, the @US_FDA approved lisocabtagene maraleucel (liso-cel) for second-line treatment of adult patients with LBCL. The efficacy of liso-cel has been evaluated in the TRANSFORM study.
Find out more here:
👉http://ow.ly/QqNu50JJj3z👈
#LymSM #HemOnc #CARTcell #ImmunoOnc
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
